Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
This study examines the efficacy and safety of tirzepatide vs insulin lispro adjunctive therapy to insulin glargine among those receiving basal insulin with inadequately controlled type 2 diabetes. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - October 3, 2023 Category: General Medicine Source Type: research
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.PRIMARY FUNDING SOURCE: Novo Nordisk A/S.PMID:37748181 | DOI:10.7326/M23-1288 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - September 25, 2023 Category: Internal Medicine Authors: Harpreet S Bajaj Jens Aberle Melanie Davies Anders Meller Donatsky Marie Frederiksen Dilek G Yavuz Amoolya Gowda Ildiko Lingvay Bruce Bode Source Type: research
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.PRIMARY FUNDING SOURCE: Novo Nordisk A/S.PMID:37748181 | DOI:10.7326/M23-1288 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - September 25, 2023 Category: Internal Medicine Authors: Harpreet S Bajaj Jens Aberle Melanie Davies Anders Meller Donatsky Marie Frederiksen Dilek G Yavuz Amoolya Gowda Ildiko Lingvay Bruce Bode Source Type: research
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.PRIMARY FUNDING SOURCE: Novo Nordisk A/S.PMID:37748181 | DOI:10.7326/M23-1288 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - September 25, 2023 Category: Internal Medicine Authors: Harpreet S Bajaj Jens Aberle Melanie Davies Anders Meller Donatsky Marie Frederiksen Dilek G Yavuz Amoolya Gowda Ildiko Lingvay Bruce Bode Source Type: research
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.PRIMARY FUNDING SOURCE: Novo Nordisk A/S.PMID:37748181 | DOI:10.7326/M23-1288 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - September 25, 2023 Category: Internal Medicine Authors: Harpreet S Bajaj Jens Aberle Melanie Davies Anders Meller Donatsky Marie Frederiksen Dilek G Yavuz Amoolya Gowda Ildiko Lingvay Bruce Bode Source Type: research
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.PRIMARY FUNDING SOURCE: Novo Nordisk A/S.PMID:37748181 | DOI:10.7326/M23-1288 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - September 25, 2023 Category: Internal Medicine Authors: Harpreet S Bajaj Jens Aberle Melanie Davies Anders Meller Donatsky Marie Frederiksen Dilek G Yavuz Amoolya Gowda Ildiko Lingvay Bruce Bode Source Type: research
Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial
CONCLUSION: Compared with OD analogues, icodec with app showed superior HbA1c reduction and improved treatment satisfaction and compliance with similarly low hypoglycemia rates.PRIMARY FUNDING SOURCE: Novo Nordisk A/S.PMID:37748181 | DOI:10.7326/M23-1288 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - September 25, 2023 Category: Internal Medicine Authors: Harpreet S Bajaj Jens Aberle Melanie Davies Anders Meller Donatsky Marie Frederiksen Dilek G Yavuz Amoolya Gowda Ildiko Lingvay Bruce Bode Source Type: research
Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study
Conclusions/interpretationWe found no difference in HbA1c reduction, hospitalisation for hypoglycaemia or all-cause mortality between Gla-300 and Deg-100 in a real-world population of new users with type 2 diabetes and moderate to end-stage chronic kidney disease. Therefore, we conclude that these two treatment options are equally effective and safe in this vulnerable population.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - September 3, 2023 Category: Endocrinology Source Type: research
Tirzepatide in Hispanic/Latino Patients with Type 2 Diabetes: A Subgroup Analysis of the SURPASS program
CONCLUSIONS: Tirzepatide significatively reduced HbA1c and body weight in Hispanic/Latino and non-Hispanic/Latino patients. Tirzepatide was generally well tolerated in both subgroups. Efficacy and safety trends were comparable between subgroups and with the overall trial populations.PMID:37602701 | DOI:10.1210/clinem/dgad495 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - August 21, 2023 Category: Endocrinology Authors: Juan Pablo Fr ías Rodolfo J Galindo Hui Wang Raleigh E Malik K Karthik Chivukula Juan M Maldonado Source Type: research
Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study
CONCLUSION: Our study showed that insulin Gla-300 maintained the glycemic control of T2DM patients who decided to fast during the holy month of Ramadan without increasing the risk of hypoglycemia. Regular self-monitoring of blood glucose levels during Ramadan is highly recommended to avoid possible complications.PMID:37581325 | DOI:10.2174/1573399820666230811152520 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - August 15, 2023 Category: Endocrinology Authors: Mohamed Hassanein Inass Shaltout Rachid Malek Samir Helmy Assaad Khalil Hajar Ballout Firas Annabi Mark Shereen Source Type: research
Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study
CONCLUSION: Our study showed that insulin Gla-300 maintained the glycemic control of T2DM patients who decided to fast during the holy month of Ramadan without increasing the risk of hypoglycemia. Regular self-monitoring of blood glucose levels during Ramadan is highly recommended to avoid possible complications.PMID:37581325 | DOI:10.2174/1573399820666230811152520 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - August 15, 2023 Category: Endocrinology Authors: Mohamed Hassanein Inass Shaltout Rachid Malek Samir Helmy Assaad Khalil Hajar Ballout Firas Annabi Mark Shereen Source Type: research
Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study
CONCLUSION: Our study showed that insulin Gla-300 maintained the glycemic control of T2DM patients who decided to fast during the holy month of Ramadan without increasing the risk of hypoglycemia. Regular self-monitoring of blood glucose levels during Ramadan is highly recommended to avoid possible complications.PMID:37581325 | DOI:10.2174/1573399820666230811152520 (Source: Current Diabetes Reviews)
Source: Current Diabetes Reviews - August 15, 2023 Category: Endocrinology Authors: Mohamed Hassanein Inass Shaltout Rachid Malek Samir Helmy Assaad Khalil Hajar Ballout Firas Annabi Mark Shereen Source Type: research
Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China
ConclusionInsulin glargine is not associated with the risk of overall and site-specific cancers compared to NPH insulin among patients with type 2 diabetes mellitus. (Source: International Journal of Diabetes in Developing Countries)
Source: International Journal of Diabetes in Developing Countries - August 10, 2023 Category: Endocrinology Source Type: research
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
ConclusionOverall, tirzepatide produced significant health and weight-related QoL improvements versus comparators in the five SURPASS studies.Clinical Trial RegistrationSURPASS-1: NCT03954834; SURPASS-2: NCT03987919; SURPASS-3: NCT03882970; SURPASS-4: NCT03730662; SURPASS-5: NCT04039503. (Source: Diabetes Therapy)
Source: Diabetes Therapy - August 1, 2023 Category: Endocrinology Source Type: research
